Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools, paying $350 million in cash and taking on near‑term milestones and royalties. The deal folds SomaLogic’s SomaScan proteomics technology and related Sengenics/Krex antibody profiling assets into Illumina’s sequencing, software and multiomics roadmap. Illumina said it will leverage its NGS ecosystem, DRAGEN software and Protein Prep assay to scale sequencing‑based protein readouts and accelerate integrated multiomics workflows. The transaction includes a CLIA/CAP lab and facilities in Boulder, Colorado, which Illumina plans to operate without immediate change. For diagnostics and biomarker development, the tie brings high‑throughput protein measurement closer to routine genomics workflows, potentially lowering cost and increasing throughput for large cohort proteomics. The move also signals intensified vertical integration as genomics companies extend into proteomics to serve drug discovery, translational research and clinical applications.